BusinessCellular Biomedicine Group Launches Phase I Clinical Trial for AlloJoin™ Off-the-Shelf Allogeneic Stem Cell Therapy for Knee OsteoarthritisBy Nasdaq OMXJan 6, 2016, 2:04 PM UTC
BusinessAchillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology and Nomination of ACH-4471, a Novel Small Molecule Factor D Inhibitor, for Clinical DevelopmentBy Nasdaq OMXDec 5, 2015, 10:00 PM UTC
BusinessAgile Therapeutics Receives Approximately $6 Million in Non-Dilutive Funding From New Jersey’s Technology Business Tax Certificate Transfer ProgramBy Nasdaq OMXDec 1, 2015, 12:45 PM UTC
